NewAmsterdam Pharma (NAMS) Accounts Payables (2021 - 2026)

NewAmsterdam Pharma has reported Accounts Payables for 6 years, with the latest figure at $8.1 million in Q1 2026.

• Quarterly Accounts Payables rose 32.91% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (up 32.91% YoY) and the FY2025 annual result came in at $9.0 million, up 89.08% from the prior year.
• Accounts Payables fell to $8.1 million in Q1 2026 per NAMS's latest filing, from $9.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $22.7 million in Q2 2023 and troughed at $3.6 million in Q3 2025.
• A 5-year average of $9.7 million and a median of $7.6 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 76.77% in 2024, then surged 89.08% in 2025.
• Over 5 years, Accounts Payables stood at $18.9 million in 2022, then fell by 10.35% to $16.9 million in 2023, then sank by 71.97% to $4.7 million in 2024, then soared by 89.08% to $9.0 million in 2025, then decreased by 9.81% to $8.1 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $8.1 million, $9.0 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.